Literature DB >> 9203572

Apafant (a PAF receptor antagonist) suppresses the early and late airway responses in guinea pigs: a comparison with antiasthmatic drugs.

K Ikegami1, H Hata, J Fuchigami, K Tanaka, Y Kohjimoto, S Uchida, K Tasaka.   

Abstract

We studied the effects of apafant (WEB 2086 BS), a specific and potent platelet activating factor (PAF) receptor antagonist, on the early and late airway responses in conscious and actively sensitized guinea pigs. An increase in airway resistance (Rs) was seen 1 min after the inhaled antigen challenge (early airway response), followed by another increase in Rs which peaked between 4 and 8 h after the provocation (late airway response). Oral administration of apafant as well as theophylline inhibited both early and late airway responses. Ozagrel, an inhibitor of thromboxane A2 synthetase, salbutamol, a beta2-adrenoceptor agonist, and dexamethasone significantly inhibited either the early or the late airway response only. Disodium cromoglycate inhibited neither the early nor the late airway response. The results showed that apafant inhibited both the early and late airway responses in sensitized guinea pigs and its effect was comparable or superior to that of anti-asthmatic drugs used clinically.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9203572     DOI: 10.1016/s0014-2999(97)83031-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  1 in total

Review 1.  Current Understanding of Platelet-Activating Factor Signaling in Central Nervous System Diseases.

Authors:  Yulong Liu; Lisa B E Shields; Zhongwen Gao; Yuanyi Wang; Yi Ping Zhang; Tianci Chu; Qingsan Zhu; Christopher B Shields; Jun Cai
Journal:  Mol Neurobiol       Date:  2016-09-09       Impact factor: 5.590

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.